⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382645 | 0.80 | — | — | |
| SCHEMBL1425908 | 0.80 | — | — | |
| SCHEMBL23721 | 0.78 | — | — | |
| SCHEMBL868391 | 0.78 | — | — | |
| SCHEMBL868487 | 0.78 | — | — | |
| SCHEMBL3970886 | 0.76 | — | — | |
| SCHEMBL28290644 | 0.74 | — | — | |
| SCHEMBL17265840 | 0.74 | — | — | |
| SCHEMBL2221134 | 0.73 | — | — | |
| SCHEMBL6911464 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612391-B2 | Cromolyn derivatives and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-12605471-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-12383528-B2 | Cromolyn esters and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240082207-A1 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION | 2024-03-14 | — | — | US | disclosed |
| US-20240067635-A1 | CROMOLYN DERIVATIVES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-20240058480-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| CN-116889562-A | Macrophage/microglial cell in neuroinflammation related to neurodegenerative diseases | 通用医疗公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-3506894-B1 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | MASSACHUSETTS GEN HOSPITAL (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-20 | — | — | US | disclosed |
| US-7632839-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| US-20080139586-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| US-20080102068-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-05-01 | — | — | US | disclosed |
| EP-1856128-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1855664-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1855685-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006078574-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078575-A2 | FLUORINATED AMINOALKYL-4-OXO-3,4-DIHYDROPYRIDO[3,4- D] PYRIMIDINES AS INHIBITORS OF MITOTIC KINESINS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078598-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |